Memphasys Limited (FRA:IG7)

Market Cap	9.26M
Revenue (ttm)	294.15K
Net Income (ttm)	-2.81M
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	12,847
Open	0.0025
Previous Close	0.0025
Day's Range	0.0025 - 0.0025
52-Week Range	0.0010 - 0.0060
Beta	n/a
RSI	52.21
Earnings Date	Nov 27, 2025

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IG7

Financial Performance

In 2025, Memphasys's revenue was 526,921, an increase of 237.77% compared to the previous year's 156,000. Losses were -5.04 million, -6.19% less than in 2024.

Financial numbers in AUD